

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Abamectin Formulation

Manufacturer or supplier's details

Company name of supplier : MSD
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Acute toxicity (Oral) : Category 5
Acute toxicity (Inhalation) : Category 4
Reproductive toxicity : Category 2
Specific target organ toxicity : Category 1 (Central nervous system)
- repeated exposure (Oral)
Specific target organ toxicity : Category 2 (Central nervous system)
- repeated exposure

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.
H332 Harmful if inhaled.
H361Df Suspected of damaging fertility. Suspected of damaging the unborn child.
H372 Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.
H373 May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

and understood.

P260 Do not breathe mist or vapors.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P271 Use only outdoors or in a well-ventilated area.

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P304 + P340 + P312 IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Call a POISON CENTER or doctor/ physician if you feel unwell.

P312 Call a POISON CENTER or doctor/ physician if you feel unwell.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention.

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Most important symptoms and effects, both acute and delayed	: Rinse mouth thoroughly with water. May be harmful if swallowed. Harmful if inhaled. Suspected of damaging fertility. Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure if swallowed. May cause damage to organs through prolonged or repeated exposure.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO ₂) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire fighting	: Exposure to combustion products may be a hazard to health.
Hazardous combustion products	: Carbon oxides
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.
Special protective equipment for fire-fighters	: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.
For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Do not breathe mist or vapors.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labeled containers.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents
Self-reactive substances and mixtures
Organic peroxides
Explosives
Gases

Abamectin Formulation

Version 3.0 Revision Date: 14.04.2025 SDS Number: 6029684-00011 Date of last issue: 06.07.2024
Date of first issue: 10.06.2020

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	TWA	15 µg/m ³ (OEB 3)	Internal
		Wipe limit	150 µg/100 cm ²	Internal

Engineering measures : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
Minimize open handling.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : light yellow

Odor : characteristic

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Odor Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	265 °C
Flash point	:	213.2 °C
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	0.90 - 0.91
Relative density	:	No data available
Density	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

May be harmful if swallowed.
Harmful if inhaled.

Product:

Acute oral toxicity	:	Acute toxicity estimate: 2,400 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: 2.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method
Acute dermal toxicity	:	Acute toxicity estimate: > 5,000 mg/kg Method: Calculation method

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Acute oral toxicity	:	LD50 (Rat): 24 mg/kg LD50 (Mouse): 10 mg/kg LDLo (Monkey): 24 mg/kg Symptoms: Dilatation of the pupil
Acute inhalation toxicity	:	LC50 (Rat): 0.023 mg/l Exposure time: 4 h Test atmosphere: dust/mist
Acute dermal toxicity	:	LD50 (Rat): 330 mg/kg LD50 (Rabbit): 2,000 mg/kg

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

II

Skin corrosion/irritation

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	: Rabbit
Result	: No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	: Rabbit
Result	: Mild eye irritation

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Test Type	: Maximization Test
Routes of exposure	: Skin contact
Result	: Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: In vitro mammalian cell gene mutation test
	Test system: Chinese hamster lung cells
	Result: negative
	Test Type: Alkaline elution assay
	Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
	Species: Mouse
	Application Route: Intraperitoneal injection

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Result: negative

Carcinogenicity

Not classified based on available information.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species	: Rat
Application Route	: Oral
Exposure time	: 105 weeks
Result	: negative

Species	: Mouse
Application Route	: Oral
Exposure time	: 93 weeks
Result	: negative

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Effects on fertility	: Test Type: Fertility Species: Rat, male Application Route: Oral Result: Effects on fertility. Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Oral Early Embryonic Development: NOAEL: 0.12 mg/kg body weight Result: Fetotoxicity.
Effects on fetal development	: Test Type: Embryo-fetal development Species: Mouse Application Route: Oral General Toxicity Maternal: NOAEL: 0.05 mg/kg body weight Developmental Toxicity: NOAEL: 0.2 mg/kg body weight Result: Cleft palate Remarks: Adverse developmental effects were observed Test Type: Embryo-fetal development Species: Rabbit Application Route: Oral Developmental Toxicity: LOAEL: 2 mg/kg body weight Result: Cleft palate, Teratogenic effects., Reduced embryonic survival Remarks: Adverse developmental effects were observed Test Type: Development Species: Rat

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Application Route: Oral
Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
Result: Teratogenic effects.

Reproductive toxicity - Assessment : Some evidence of adverse effects on sexual function and fertility, based on animal experiments., Some evidence of adverse effects on development, based on animal experiments.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Central nervous system) through prolonged or repeated exposure if swallowed.

May cause damage to organs (Central nervous system) through prolonged or repeated exposure.

Components:**abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Routes of exposure : Ingestion
Target Organs : Central nervous system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Species : Rat
NOAEL : 1.5 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Mouse
NOAEL : 4.0 mg/kg
Application Route : Oral
Exposure time : 24 Months
Target Organs : Central nervous system
Symptoms : Tremors, ataxia

Species : Dog
NOAEL : 0.25 mg/kg
LOAEL : 0.5 mg/kg
Application Route : Oral
Exposure time : 53 Weeks
Target Organs : Central nervous system
Symptoms : Tremors, weight loss
Remarks : mortality observed

Species : Monkey
NOAEL : 1.0 mg/kg

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Application Route	:	Oral
Exposure time	:	14 Weeks
Target Organs	:	Central nervous system

Aspiration toxicity

Not classified based on available information.

Experience with human exposure**Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Ingestion	:	Symptoms: May cause, Tremors, Diarrhea, central nervous system effects, Salivation, tearing
-----------	---	---

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****abamectin (combination of avermectin B1a and avermectin B1b) (ISO):**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 3.2 µg/l Exposure time: 96 h
		LC50 (Lepomis macrochirus (Bluegill sunfish)): 9.6 µg/l Exposure time: 96 h
		LC50 (Ictalurus punctatus (channel catfish)): 24 µg/l Exposure time: 96 h
		LC50 (Cyprinus carpio (Carp)): 42 µg/l Exposure time: 96 h
		LC50 (Cyprinodon variegatus (sheepshead minnow)): 15 µg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Americamysis): 0.022 µg/l Exposure time: 96 h
		EC50 (Daphnia magna (Water flea)): 0.34 µg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	EC50 (Pseudokirchneriella subcapitata (green algae)): 100 mg/l Exposure time: 72 h
Toxicity to fish (Chronic toxicity)	:	NOEC (Pimephales promelas (fathead minnow)): 0.52 µg/l Exposure time: 32 d
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): 0.03 µg/l Exposure time: 21 d
		NOEC (Mysidopsis bahia (opossum shrimp)): 0.0035 µg/l Exposure time: 28 d

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition

Persistence and degradability**Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Stability in water : Hydrolysis: 50 %(< 12 h)

Bioaccumulative potential**Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Bioaccumulation : Bioconcentration factor (BCF): 52

Partition coefficient: n-octanol/water : log Pow: 4

Mobility in soil**Components:**

abamectin (combination of avermectin B1a and avermectin B1b) (ISO):

Distribution among environmental compartments : log Koc: > 3.6

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

UN number	: UN 3082
Proper shipping name	: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S. (abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class	: 9
Packing group	: III

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**NOM-002-SCT**

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(abamectin (combination of avermectin B1a and avermectin B1b) (ISO), 2,6-Di-tert-butyl-p-cresol)
Class : 9
Packing group : III
Labels : 9

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Federal Law for the control of chemical precursors, : Not applicable
essential chemical products and machinery for

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

producing capsules, tablets and pills.

The ingredients of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SECTION 16. OTHER INFORMATION

Revision Date	:	14.04.2025
Date format	:	dd.mm.yyyy

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
--	---	---

Abamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.07.2024
3.0	14.04.2025	6029684-00011	Date of first issue: 10.06.2020

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8